TWST stock surged 6.8% higher on November 1, 2021, and has been trending higher since the company announced the launch of its Exome 2.0 product.
- 1 Twist Bioscience Launches Exome 2.0 for Genomics Research
- 2 TWST stock coverage transferred at Cowen
- 3 Twist Bioscience and the Broad Institute Create Custom Whole Exome Target Enrichment Panel for Clinical Research
- 4 VIDEO Broad’s Director of Genomics Research and Development
- 5 TWST Stock Technical Analysis
Twist Bioscience Launches Exome 2.0 for Genomics Research
On October 20, 2021, Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced the launch of its Exome 2.0, featuring the most comprehensive coverage of protein-coding and noncoding regions of the genome, as well as best-in-class performance to reduce downstream sequencing costs.
“We have been working with Twist for the last three years and recently adapted the Twist Exome 2.0 for our recent work for various indications, especially for unexplained developmental disorders,” said Oliver Wachter of the Center for Human Genetics and Laboratory Diagnostics in Germany (MVZ-Martinsried GmbH). “The content, performance, and quality are the best we have experienced from any provider, and we didn’t have to choose between robust content and performance.”
“Twist continues to expand our portfolio of high-quality, best-in-class life science tools,” said Emily M. Leproust, Ph.D., CEO, and co-founder of Twist Bioscience. “With the launch of Exome 2.0, we now offer a complete portfolio of flexible, comprehensive exome options to support genomics researchers looking to identify the underpinnings of disease.”
The Twist Exome 2.0 is an exome panel designed with thoughtfully curated content that includes comprehensive coverage of genes responsible for rare diseases, inherited disorders, and germline cancers in humans. With a fully automatable workflow, Twist Exome 2.0 outperformed available exomes on the market today, demonstrating higher uniformity and a higher on-target rate, as well as lower drop out and duplicate read rates, resulting in better data and lower sequencing costs. Exome 2.0 provides best-in-class coverage of protein-coding regions from major genetic databases (RefSeq, CCDS, GenCode, Clinvar, ACMG73, and more) and coverage of clinically relevant noncoding pathogenic and likely pathogenic variants. Twist Exome 2.0 can be customized for a wide range of applications and uses while providing workflow flexibility through Fast Hybridization (<4 hrs) or the new Standard Hybridization v2 (overnight) reagents. All Twist exomes contain double-stranded DNA probes for complete coverage, customized to specific needs, and work with Twist’s library preparation and target enrichment workflows. Twist Exome 2.0 works with the recently launched enzymatic fragmentation 2.0 kit to provide unmatched performance and efficiency in sequencing-ready libraries.
To learn more about the company, visit https://www.twistbioscience.com
TWST stock coverage transferred at Cowen
On October 14, 2021, Cowen transferred coverage of TWST stock to analyst Dan Brennan, who maintained an Outperform rating on the stock.
Twist Bioscience and the Broad Institute Create Custom Whole Exome Target Enrichment Panel for Clinical Research
On October 13, 2021, Twist Bioscience Corporation (NASDAQ: TWST) announced an agreement with the Broad Institute for the distribution of a customized next-generation sequencing (NGS) target enrichment exome panel designed for the identification and research of a wide range of cancer, rare and inherited disease genes from patient samples. Twist will market this expert-developed exome panel as the Twist Alliance Clinical Research Exome.
The Twist Alliance Clinical Research Exome helps support the Broad Institute Genomics Platform and was designed using validated data from clinical patient samples. The panel leverages Twist’s flexible NGS platform to easily and quickly customize the content, resulting in a comprehensive survey of the exome with supplemental enrichment of clinically relevant areas of the genome related to cancer and rare and inherited diseases. By leveraging the best-in-class uniformity of Twist NGS probes, the assay enables a per-sample cost and throughput efficiency that Broad has already leveraged to process more than 250,000 samples to date, keeping it on the leading edge of exome sequencing.
“Exome sequencing has long been a key part of our sequencing efforts for large cancer and germline research studies. Our development with Twist has leveraged many of our learnings on the technical side and pulls in knowledge from collaborating investigators to provide an enhanced exome that will increasingly span both research and clinical applications in which results are returned to patients,” said Stacey Gabriel, senior director of the Broad Institute Genomics Platform.
The Twist Alliance Clinical Research Exome will be available for customers in mid-October. The complete design of this panel includes the Twist Core exome, the mitochondrial genome, and additional validated coding and non-exonic regions of interest such as the ACMG73 genes, supplemental coverage of parts from OMIM, and COSMIC, and specific Broad-defined targets.
VIDEO Broad’s Director of Genomics Research and Development
Brendan Blumenstiel presenting data on the panel:
“Typically, in cancer research studies, there is a great need to focus sequencing efforts on particular genes or mutations but often with a small number of samples available. Leveraging the Broad’s vast expertise, together we have developed a specialized custom panel that enables deeper sequencing, producing validated genetic variants that could be used for therapeutic intervention,” said Emily M. Leproust, Ph.D., chief executive officer and co-founder of Twist Bioscience. “We are thrilled to bring this important tool to our customers to drive deep insights into research and potential therapeutic development.”
In partnership with leading research institutions worldwide, Twist has curated a collection of high-quality target enrichment panels for applications ranging from carrier screening to cancer diagnostics and whole-exome sequencing. The Twist Alliance Panels combine the strengths of a precise, highly uniform oligonucleotide synthesis with the specialty expertise of leading scientific research partners.
Well-designed, custom target enrichment panels enable increased sequencing depth on target genes while reducing overall sequencing. This allows for more sensitive detection of target sequences and higher confidence variant detection.
TWST Stock Technical Analysis
Large players volume has taken a turn higher and we had a Pocket Pivot signal (blue dot) on November 1, 2021. Both the short-term and long-term trends are positive. This is a very positive sign. Although TWST has an excellent technical rating, it does not present a decent entry opportunity at the moment. Price movement has been a little bit too volatile to find a nice entry and exit point. It is probably a good idea to wait for a consolidation first. Click here to sign up for email alerts on when TWST stock is a good entry.